Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients

NCT05458752 | Completed

• 1 other identifier: 2020PI184-Pre-existing datas
• Study Type: observational
• Target: 133
• Locations: 1 country
• Sites: 1

Brief Summary

Pneumocystis jirovecii pneumonia (PjP) is a rare infectiouse disease with a high level of mortality. PjP is a classical opportunistic infection which concern HIV infected and immunocompromised patients. During the past decade, several therapeutic's progresses have been done in oncology, immunology and hematology. As a consequence, patients benefited of greater treatment efficacy but are exposed to a higher risk of opportunistic infections as PjP. The investigators hypothesis is that PjP incidence increase and its form is depending of underlying immune conditions. The investigators aim to describe its incidence, the PjP forms depending on comorbidities and to identifiy pronostics factors.

Conditions

Pneumocystis Jirovecii Infection

Keywords

pneumocystis jirovecii pneumonia; HIV-free patients

Outcome Measures

Primary Outcomes (1)

• Incidence of Pneumocystis jirovecii pneumonia in HIV-free patients

  Number of cases / number of patients treated for a predisposing disease (heamotological or imunological disease, or cancer...)

  Between the first january 2004 and the 31th december 2021

Secondary Outcomes (26)

• To describe the age of giv free patients with Pneumocystis jirovecci pneumonia

  Between the first january 2004 and the 31th december 2021

• To describe the body mass index of HIV free patients with Pneumocystis jirovecci pneumonia

  Between the first january 2004 and the 31th december 2021

• To describe the Charlson comorbidity index of HIV free patients with Pneumocystis jirovecci pneumonia

  Between the first january 2004 and the 31th december 2021

• To describe the comoribidites of HIV-free patients with Pneumocystis jirovecci pneumonia

  Between the first january 2004 and the 31th december 2021

• To describe the previous medications used by HIV free patients with Pneumocystis jirovecci pneumonia

  Between the first january 2004 and the 31th december 2021

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients without HIV-infection hospitalised in Nancy hospital between 2004 and 2021 for Pneumocystis jirovecii pneumonia

You may qualify if:

• Underlying immune condition at risk of Pneumocystis jirovecii pneumonia excluding HIV infection
• Clinical, biological and radiological presentation which evoke Pneumocystis jirovecii pneumonia
• Microbiological confirmation by respiratory specimen analyses ( specific coloration and/or IFI and/or PRC)

You may not qualify if:

• No microbiological confirmation by respiratory specimen analyses
• Proved HIV infection
• Patient denied to particpate

Sponsors & Collaborators

• Central Hospital, Nancy, France: lead

Study Sites (1)

Université de Lorraine, CHRU Nancy and APEMAC

Vandœuvre-lès-Nancy, Lorraine, 54511, France

Location

MeSH Terms

Conditions

Pneumocystis Infections; Pneumonia, Pneumocystis

Condition Hierarchy (Ancestors)

Mycoses; Bacterial Infections and Mycoses; Infections; Lung Diseases, Fungal; Respiratory Tract Infections; Pneumonia; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor

Study Record Dates

• First Submitted: June 28, 2022
• First Posted: July 14, 2022
• Study Start: April 1, 2020
• Primary Completion: June 1, 2023
• Study Completion: July 1, 2023
• Last Updated: July 5, 2023

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)